Relief of migraine attack — hepants

Abstract

Thе review presents the mechanism of action of a new class of targeted drugs for the treatment of migraine with CGRP gepant receptor antagonists — gepants. Currently, two drugs — ubrogepant and rimegepant are approved by the FDA for the relief of acute migraine attacks in the United States. In the Russian Federation, none of the drugs of this new class is registered, however, this is possible in the near future. The review presents the results of RCTs that demonstrated their effectiveness in comparison with triptans and placebo, as well as good tolerability and safety. Rimegepant and ubrogepant cause minimal side effects and are safe for people with cardiovascular diseases. Gepants may provide an alternative for migraine patients who do not tolerate the side effects observed with triptans, as well as the main therapy.